An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

PHASE3UnknownINTERVENTIONAL
Enrollment

486

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

April 30, 2013

Study Completion Date

December 31, 2016

Conditions
Ovarian Cancer
Interventions
DRUG

cediranib

Once-daily oral tablet starting dose 20mg

Trial Locations (1)

WC1E 6BT

University College London, London

All Listed Sponsors
collaborator

Cancer Research UK

OTHER

collaborator

National Health and Medical Research Council, Australia

OTHER

collaborator

Australia New Zealand Gynaecological Oncology Group

OTHER

collaborator

NCIC Clinical Trials Group

NETWORK

collaborator

Grupo Español de Investigación en Cáncer de Ovario

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

Medical Research Council

OTHER_GOV